STSerhan Tanju

Serhan Tanju

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Serhan Tanju has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparison of Paravertebral Block and Serratus Posterior Superior Intercostal Plane Block for Postoperative Analgesia After Video-Assisted Thoracoscopic Surgery: A Prospective, Randomized Controlled Trial

    by Mete Manici, Yasemin Sincer, Doruk Yaylak, Muhammet Selman Söğüt, Kamil Darçın, İlAyda Kalyoncu, Kadir Burak Özer, Serhan Tanju, Yavuz Gürkan

  • Open Access

    Induction Chemoimmunotherapy Followed by Consolidative Hypofractionated Radiotherapy for Unresectable Locally Advanced NSCLC: A Real-World Outcomes Analysis

    by Caglayan Selenge Beduk Esen, Sukran Celikarslan, Duygu Sezen, Fatih Selcukbiricik, Kerim Kaban, Metin Kanitez, Perran Fulden Yumuk, Nil Molinas Mandel, Levent Tabak, Ezgi Cesur, et al.

    Purpose/Objective: To evaluate the safety and failure patterns of consolidative hypofractionated thoracic radiotherapy (RT) following induction chemoimmunotherapy in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). Materials/Methods: This retrospective study included 34 patients treated between 2019 and 2025. All patients received induction chemoimmunotherapy followed by consolidative hypofractionated RT based on multidisciplinary tumor board recommendations. The primary endpoint was local recurrence (LR); secondary endpoints were regional recurrence (RR), distant metastasis (DM), overall survival (OS), progression-free survival (PFS), and treatment-related toxicity. Results: Median age was 64 years, and median PD-L1 expression was 20%. Most patients had stage III disease; squamous cell carcinoma (56%) and adenocarcinoma (38%) were the predominant histologies. The most common systemic regimen was carboplatin/paclitaxel plus nivolumab, with a median of four induction cycles. Post-induction response was complete in 21%, partial in 62%, stable in 12%, and progressive in 6%. Median RT dose was 52.5 Gy in 15 fractions, and maintenance immunotherapy was administered in 79%. At a median follow-up of 16.7 months, using cumulative incidence functions with death treated as a competing event, the 1- and 2-year cumulative incidences of local failure were 6.9% and 14.7%, respectively. The corresponding cumulative incidences of regional failure were 10.2% and 18.8%, while distant metastasis incidences were 15.9% and 39.2%. No isolated local or regional recurrences occurred. One- and two-year OS rates were 86% and 81%, and corresponding PFS rates were 76% and 54%. No grade 4–5 RT-related toxicity occurred; one grade 5 immune-related pneumonitis was observed. Conclusions: Consolidative hypofractionated RT following chemoimmunotherapy appears feasible and associated with favorable outcomes, supporting further prospective investigation.

  • Segmentectomy or Lobectomy in T1N0M0 Non-Small Cell Lung Carcinomas: The Prognostic Role of Histology and Vascular Invasion

    by Gizem Özçıbık Işık, Akif Turna, Serhan Tanju, Celal Buğra Sezen, Hasan Volkan Kara, Hüseyin Melek, Ali Çelik, Muhammet Sayan, Mustafa Vedat Doğru, Suat Erus, et al.

  • Open Access

    Response to Letter to the Editor: Additional insights into the outcomes after combined heart-lung surgery

    by Mehmet Şanser Ateş, Zümrüt Tuba Demirözü, Suat Erus, Eray Aksoy, Kadir Burak Özer, Sami Gürkahraman, Ekin Ezgi Cesur, Serhan Tanju

  • Open Access

    The outcomes of concomitant off-pump coronary artery bypass grafting and pulmonary operations

    by Mehmet Şanser Ateş, Zümrüt Tuba Demirözü, Suat Erus, Eray Aksoy, Kadir Burak Özer, Sami Gürkahraman, Ekin Ezgi Cesur, Serhan Tanju

    Background: This study aims to analyze the early- and long-term outcomes of concomitant off-pump coronary artery bypass grafting and pulmonary resection for lung cancer or a thoracic mass. Methods: Twenty-three patients (17 females, 6 males; mean age: 69.7±6.5 years; range, 59 to 83 years) who underwent concomitant off-pump coronary artery bypass grafting and thoracic surgery procedures for lung cancer or a thoracic mass between March 2018 and February 2024 were included in the retrospective study. The surgical approach was median sternotomy for off-pump coronary artery bypass grafting, and video-assisted thoracoscopic surgery was preferred for lung tumor resections. Mortality, major adverse cardiac events, cerebrovascular events, and duration of hospital stay were evaluated. Results: There were no postoperative deaths or perioperative myocardial infarctions. None of the patients experienced pneumothorax or atelectasis. None of the patients sustained excessive blood loss requiring reoperation. Arterial grafts were the first choice during coronary artery bypass grafting. Wedge resections, lobectomies, segmentectomies were performed in the subsequent video-assisted thoracic surgery. All patients were followed for six to 86 months. Four patients died during the postoperative one-year period, and one patient died at postoperative 29 months due to cancer relapse. The overall one-year survival rate was 86.5%, and three- and five-year survival rates were 74% and 74%, respectively. Conclusion: The video-assisted thoracoscopic surgery approach provides a more favorable perspective for pulmonary resection and mediastinal lymph node dissection, which has importance in patients’ final diagnosis, than the sternal view due to more ample, wider workspace. Combined off-pump coronary artery bypass grafting and pulmonary resection in patients with lung cancer is safe and effective and reduces possible complications of a second major surgery.


  • Open Access

    The Practice of Antimicrobial Stewardship in Thoracic Surgery and its Effectiveness

    by Bahar Madran, Siran Keske, Serhan Tanju, Ekin Ezgi Cesur, Selin Pala, Sukra Dilege, Onder Ergonul

    Surgical site infections (SSIs) are a significant global problem, and their burden increases with emerging antimicrobial resistance. Globally, around 12.3% of surgical patients suffer from SSIs annually, with higher rates in low-income countries (23.2%) compared to high-income countries (9.4%). Inappropriate antibiotic use not only escalates the rate of (...)


  • Scrape cytology and radiological solid size correlation can be used in the intraoperative management of subsolid lung nodules

    by Pınar Bulutay, Çetin Atasoy, Suat Erus, Serhan Tanju, Şükrü Dilege, Pınar Fırat

    Background: The term radiologic subsolid lung nodule (SLN) represents a heterogeneous group of non‐neoplastic and neoplastic lesions. Intraoperative evaluation (IO) is often required to differentiate and diagnose. The current study aims to investigate the feasibility and reliability of scrape cytology (SC) and radiologic solid size correlation for the IO diagnosis of SLNs.Methods: Sixty‐eight patients with SLN signs were eligible to take part in the study due to intraoperatively prepared SC slides. We managed to complete the blind radiologic solid size measurement and cytologic evaluation retrospectively. Cases were grouped into three categories based on their cytological features: Group‐0 (Benign), Group‐1 (mild atypical features), and Group‐2 (severe atypical features/unequivocally carcinoma). IO diagnoses were given by combining the radiologic solid size and cytological findings.Results: Cytological features of Group‐1 were observed in 100%, 93%, 32.5%, and 17% of the AIS, MIA, IA, and benign lesions, respectively. Cytological features of Group‐2 were observed in 67.5%, and 7% of the IA and MIA, respectively. By combining cytology with radiologic solid size, 100%, 85%, 71%, and 83% of the AIS, IA, MIA, and benign lesions respectively were diagnosed correctly. Fifteen (15%) percent of the IA cases were underdiagnosed as MIA since their radiological solid sizes were less than 0.5 cm with cytological features of Group‐1. Conversely, 29% of the MIA cases were overdiagnosed as IA since their radiological solid sizes were greater than 0.5 cm.Conclusion: SLNs should be handled with caution in terms of IO management. SC and radiologic solid size correlation both provide a practical and tissue‐protecting approach for the IO evaluation of SLNs, ensuring a high consistency between IO and definitive diagnosis.

  • Open Access

    KRAS signaling in malignant pleural mesothelioma

    by Antonia Marazioti, Anthi C Krontira, Sabine J Behrend, Georgia A Giotopoulou, Giannoula Ntaliarda, Christophe Blanquart, Hasan Bayram, Marianthi Iliopoulou, Malamati Vreka, Lilith Trassl, et al.

    Malignant pleural mesothelioma (MPM) arises from mesothelial cells lining the pleural cavity of asbestos‐exposed individuals and rapidly leads to death. MPM harbors loss‐of‐function mutations in BAP1 , NF2 , CDKN2A , and TP53 , but isolated deletion of these genes alone in mice does not cause MPM and mouse models of the disease are sparse. Here, we show that a proportion of human MPM harbor point mutations, copy number alterations, and overexpression of KRAS with or without TP53 changes. These are likely pathogenic, since ectopic expression of mutant KRAS G12D in the pleural mesothelium of conditional mice causes epithelioid MPM and cooperates with TP53 deletion to drive a more aggressive disease form with biphasic features and pleural effusions. Murine MPM cell lines derived from these tumors carry the initiating KRAS G12D lesions, secondary Bap1 alterations, and human MPM‐like gene expression profiles. Moreover, they are transplantable and actionable by KRAS inhibition. Our results indicate that KRAS alterations alone or in accomplice with TP53 alterations likely play an important and underestimated role in a proportion of patients with MPM, which warrants further exploration.


  • Open Access

    The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lung adenocarcinomas?

    by Pınar Bulutay, Pınar Firat, Handan Zeren, Suat Erus, Serhan Tanju, Şükrü Dilege

    Background/aim: Programmed death ligand-1 (PD-L1) is a predictive marker for immunotherapeutic agents. However, heterogeneous staining of PD-L1 can cause false-negative results. The aim of this study is to evaluate the importance of histological patterns on PD-L1 staining heterogeneity in lung adenocarcinomas (LAC). Materials and methods: PD-L1 immunohistochemistry (IHC) stain was performed to two different tissue cores of 128 LAC cases, and cut-off values are given for grouping the cases according to the percentage of staining (1%-10%, 11%-49%, 50%-100%). Staining rates between cores were compared and analyzed by their histological patterns. Also, the relation of the PD-L1 expression with the clinicopathological characteristics of the cases was analyzed. Results: Overall, PD-L1 expression was observed in 53 of 128 cases (41.4%, 1% cut-off), 23.5% of them were positive at 10% cut-off and 14.1% at 50% cut-off. PD-L1 expression was significantly related to the high grade micropapillary and solid patterns of adenocarcinomas (p:0.01). Staining cut-offs were mostly similar between cores (43/50, 86%) (k:0.843). However, 14% of them were positive only in one core (7 of 50). This false negativity was mostly related to the histological patterns. Conclusion: Our data reveal the heterogeneous staining of PD-L1 expression, also micropapillary and solid patterns show higher rates of PDL expression. Therewithal, these findings also highlight the importance of taking into consideration of histological patterns, when choosing a paraffin block for the PDL1.


  • Extended Resection: Is It Feasible for Pulmonary Metastases?

    by Serhan Tanju, Sedat Ziyade, Suat Erus, Yusuf Bayrak, Alper Toker, Sukru Dilege

    Extended resections may be necessary to achieve tumor-free borders for secondary pulmonary malignancies. This study was performed to analyze the outcomes that result from extended resections of pulmonary metastases. Between February 1991 and December 2008, a total of 25 extended pulmonary resections (resection of the chest wall and diaphragm, vascular procedures, sleeve resections, pneumonectomies, atrial resections, and completion pneumonectomies) were performed on 250 patients undergoing 319 metastasectomy procedures. The extended resection group was analyzed in terms of disease-free interval, type of resection, operative morbidity, mortality, and survival and was then compared with patients who underwent lobar or sublobar resections. The extended resection group consisted of 14 male and 11 female patients. The mean disease-free interval was 36.02 (minimum 6, maximum 132) months. The extended resection rate was 10%. After 30 days, all patients were alive. For all extended metastasectomy groups, actuarial 5-year survival rates from the time of the extended metastasectomy were 16.3%. Mean survival times of patients who underwent extended resection and lobar or sublobar resection were 40 months (SD = 11) (95% confidence interval, 19–61) and 20 months (SD = 3) (95% confidence interval, 14–26), respectively. This difference was not statistically significant (P = 0.09) (Fig. 2). In the subgroup analysis, survival in the extended resections and lobar or sublobar resections groups was not statistically significant (osteosarcoma, P = 0.758; epithelial tumor, P = 0.11). Extended resections, which can be performed during pulmonary metastasectomies of patients with tumor-free surgical borders, may establish curative benefits, with low rates of mortality and morbidity.